Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 7/20 | 0.49 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | PDCD1 | Q15116 | 7/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 7/20 | 0.43 |
| ▸ | HTR1D | P28221 | 3/20 | 0.40 |
| ▸ | HTR1B | P28222 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4907017 | 0.88 | ROCK2 (0.38) | ROCK2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4910570 | 0.87 | ROCK2 (0.47) | ROCK2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4915030 | 0.85 | PDE4A (0.47) | ROCK2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4904274 | 0.85 | PDE4A (0.47) | ROCK2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4910278 | 0.84 | ROCK2 (0.47) | ROCK2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4910107 | 0.84 | ROCK2 (0.47) | ROCK2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4909374 | 0.83 | AVPR2 (0.38) | ROCK2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4910197 | 0.83 | KDM4E (0.44) | CD274ALDH1A1 | |
| SCHEMBL5242475 | 0.83 | AKR1C3 (0.46) | ROCK2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5242709 | 0.82 | ROCK2 (0.41) | ROCK2PDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076760-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | WAKAMOTO PHARMACEUTICAL CO., LTD (JP) | 2008-03-27 | — | — | US | disclosed |
| US-20080076760-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | WAKAMOTO PHARMACEUTICAL CO., LTD (JP) | 2008-03-27 | — | — | US | disclosed |
| US-20080076760-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | WAKAMOTO PHARMACEUTICAL CO., LTD (JP) | 2008-03-27 | — | — | US | disclosed |
| EP-1820799-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | Wakamoto Pharmaceutical Co., Ltd. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076760-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | GABRA5, GABRA1, GABRB1 | ROCK2 4050/4885PDE4A 2283/4885PDE4B 1460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.